Celularity Inc (CELU) Stock Price, Quote & News

Company Profile

Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and deg...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 768 2170

Website: www.celularity.com

Address:

170 Park Avenue, Florham Park, United States

Nosay Jul. 3 at 3:54 PM

$CELU last year Q1 and Q2 both came out late on the same day August 29th. The stock price had been doing well and the market obviously did not like the earnings. Hopefully this year is the exact opposite. Our Q1 and Q2 can’t be worse than last year. Likely this won’t run until those numbers come out. I expect guidance for 2nd half to be very good as well.

2 · Reply

NuclearMan Jul. 2 at 11:09 AM

$CELU This company has USD7.8m on the books but Barach holds the keys. He is loaning liquidity so that Bob has a bridge. The 8K was at the termination of a descending wedge so there is some method in this. Still needs the delinquent 10Q, though. Algos won't buy without it.

0 · Reply

1948Je Jun. 30 at 10:31 PM

$CELU Every stocks run a few hundred percent, Our time will be soon

0 · Reply

Nosay Jun. 30 at 8:23 PM

$CELU why only 1 million. And why is Phillip Barach willing to offer 4% interest. He’s lending 1 million and only collecting 3333 off of it. That’s not a big reward. Something is coming within the month for sure.

1 · Reply

focafoca99 Jun. 30 at 1:28 PM

$CELU took a $1 million loan from the Barach Family Trust, 4% interest, maturing 30 days after closing or receipt of financing.

0 · Reply

NuclearMan Jun. 30 at 12:54 PM

$CELU Financials for this company may not be bad now. They have USD7.8M cash and retired most outstanding debt. Their remaining liabilities are USD7M to Barach plus factory operating costs (which should be offset by the ongoing Nexgel deal). This is all guestimates though, based on the 10K and applying recent data to that. But the market won't recognise any improvements unless Bob files the numbers. This is why his shareholder letter was ignored by algos.

0 · Reply

NuclearMan Jun. 30 at 12:36 PM

$CELU Celularity has until 28 July to file the 10Q. It goes delinquent on minimum bid in eleven trading days. So given the rules that kick in after 30 days under a dollar, Celularity will face a panel for the 10Q while also delinquent on MVLS *and* the minimum bid. My guess is the auditors have an issue with the classification of Barach's position, but whatever the reason, the missing 10Q is of critical importance to the company staying listed.

0 · Reply

wolf_of_crypto_street Jun. 30 at 12:28 PM

$CELU this shit is headed to zero

0 · Reply

luckydog2 Jun. 30 at 4:41 AM

$CELU For anyone interested in learning about the many cell therapies offered at Fountain Life: https://www.reddit.com/r/CelularityNews/s/G52nijYh0c

0 · Reply

humorme Jun. 29 at 5:01 PM

$CELU Has anyone heard anything about a potential meeting between Hariri and RFK Jr. regarding government funding? I reached out to IR and got no response. I recall reading about this but can’t find it about 6 weeks ago.

1 · Reply

Penny Stocks: Why Is Celularity (CELU) Stock Trending Today?

NXGL

2026-06-04T12:20:25.000Z - 4 weeks ago

Celularity announces cenplacel-L availability for investigational use in Florida

Jun 4, 2026, 8:00 AM EDT - 4 weeks ago

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

Jun 3, 2026, 4:15 PM EDT - 4 weeks ago

Celularity Releases CEO Letter to Shareholders

Jun 3, 2026, 8:00 AM EDT - 4 weeks ago

Celularity Appoints Rick Gonzalez as Chief Commercial Officer

May 29, 2026, 5:15 PM EDT - 5 weeks ago

Celularity Receives Nasdaq Notice Regarding Form 10-Q

May 1, 2026, 4:30 PM EDT - 2 months ago

Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation

Apr 30, 2026, 7:00 AM EDT - 2 months ago

Celularity Annual report: Q4 2025

Apr 27, 2026, 9:00 AM EDT - 2 months ago

NEXGEL Appoints Ian Blackman as Chief Financial Officer

2026-04-21T15:06:20.000Z - 2 months ago

NexGel closes acquisition of products from Celularity

NXGL

2026-04-21T13:07:46.000Z - 2 months ago

Celularity announces closing of transaction with NexGel

Apr 21, 2026, 8:30 AM EDT - 2 months ago

Celularity Announces Closing of Transaction with NexGel

Apr 17, 2026, 4:35 PM EDT - 2 months ago

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

2026-03-12T12:55:45.000Z - 4 months ago

NexGel announces terms of agreement of license for products from Celularity

NXGL

2026-03-12T12:35:15.000Z - 4 months ago

Celularity reiterates strategic commercialization partnership with NEXGEL

NXGL

Mar 12, 2026, 8:30 AM EDT - 4 months ago

Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

2026-03-10T12:51:55.000Z - 4 months ago

NexGel sign agreement to license, acquire portfolio of products from Celularity

NXGL

2026-03-10T12:41:03.000Z - 4 months ago

Celularity secures $35M strategic license deal

Mar 10, 2026, 8:30 AM EDT - 4 months ago

Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy

2026-02-10T13:41:35.000Z - 5 months ago

Celularity receives $12.2M from sale of New Jersey net operating losses

Feb 10, 2026, 8:30 AM EST - 5 months ago

Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses

2025-12-31T21:20:16.000Z - 6 months ago

Celularity files to sell 14.08M shares of Class A common stock for holders

Dec 31, 2025, 7:00 AM EST - 6 months ago

Celularity Registration statement: Registration Filing

Dec 26, 2025, 8:30 AM EST - 6 months ago

Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations

Dec 22, 2025, 4:01 PM EST - 6 months ago

Celularity Announces Closing of Financing Transactions

2025-12-19T21:20:21.000Z - 7 months ago

Celularity files to sell 15.95M shares of Class A common stock for holders

Dec 19, 2025, 7:00 AM EST - 7 months ago

Celularity Registration statement: Registration Filing

2025-12-18T19:15:11.000Z - 7 months ago

Celularity announces up to $12M of capital from Philip Barach

Dec 18, 2025, 2:10 PM EST - 7 months ago

Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision

Nov 14, 2025, 7:00 AM EST - 8 months ago

Celularity Quarterly report: Q3 2025

Nov 7, 2025, 7:00 AM EST - 8 months ago

Celularity Proxy statement: Proxy Filing

Nov 7, 2025, 7:00 AM EST - 8 months ago

Celularity Proxy statement: Proxy Filing

2025-10-30T12:20:52.000Z - 8 months ago

Celularity, DefEYE partner to advance regenerative therapies in eye care

Oct 30, 2025, 8:00 AM EDT - 8 months ago

Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care

2025-10-14T12:55:36.000Z - 9 months ago

Celularity announces publication of Phase 2 study on PDA-002

Oct 14, 2025, 8:45 AM EDT - 9 months ago

Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease

2025-09-03T12:10:50.000Z - 10 months ago

Celularity reports Q1 EPS (84c) vs ($1.03) last year

2025-09-03T12:10:44.000Z - 10 months ago

Celularity regains compliance with Nasdaq listing rule

Sep 3, 2025, 8:00 AM EDT - 10 months ago

Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance

Aug 29, 2025, 9:30 AM EDT - 11 months ago

Celularity Quarterly report: Q2 2025

Aug 29, 2025, 12:00 AM EDT - 11 months ago

Celularity Quarterly report: Q1 2025

2025-08-22T21:35:07.000Z - 11 months ago

Celularity receives noncompliance notice from Nasdaq

2025-08-18T12:20:27.000Z - 11 months ago

Celularity completes balance sheet restructuring, retires $41.6M in debt

Aug 18, 2025, 8:00 AM EDT - 11 months ago

Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt

Jul 9, 2025, 8:30 AM EDT - 1 year ago

Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law

2025-07-01T12:40:49.000Z - 1 year ago

Celularity hails new Florida law opening patient access to stem cell therapies

Jul 1, 2025, 8:30 AM EDT - 1 year ago

Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies

Jun 10, 2025, 4:15 PM EDT - 1 year ago

Celularity Announces Chief Financial Officer Transition

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology

May 9, 2025, 4:00 PM EDT - 1 year ago

Celularity Earnings release: Q4 2024

May 9, 2025, 4:00 PM EDT - 1 year ago

Celularity Annual report: Q4 2024

May 9, 2025, 9:15 AM EDT - 1 year ago

Celularity Announces Full Year 2024 Operating and Financial Results

Apr 25, 2025, 5:30 PM EDT - 1 year ago

Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products

Feb 25, 2025, 8:00 AM EST - 1 year ago

Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products

Feb 24, 2025, 8:00 AM EST - 1 year ago

Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company

Feb 13, 2025, 7:00 AM EST - 1 year ago

Celularity Registration statement: Registration Filing

Jan 30, 2025, 7:00 AM EST - 1 year ago

Celularity Registration statement: Registration Filing

Dec 10, 2024, 8:00 AM EST - 1 year ago

Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

Dec 6, 2024, 8:00 AM EST - 1 year ago

Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023

Dec 5, 2024, 6:00 PM EST - 1 year ago

Celularity Quarterly report: Q3 2024

Nov 27, 2024, 5:00 PM EST - 1 year ago

Celularity Inc. Announces Receipt of Nasdaq Notification

Nov 20, 2024, 8:30 AM EST - 1 year ago

Celularity's Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific

Nov 19, 2024, 7:00 AM EST - 1 year ago

Celularity Proxy statement: Proxy Filing

Nov 6, 2024, 6:00 PM EST - 1 year ago

Celularity Quarterly report: Q2 2024

Oct 23, 2024, 8:30 AM EDT - 1 year ago

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

Oct 18, 2024, 6:00 PM EDT - 1 year ago

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal

Oct 16, 2024, 5:15 PM EDT - 1 year ago

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

Oct 16, 2024, 3:30 AM EDT - 1 year ago

Celularity Quarterly report: Q1 2024

Sep 5, 2024, 4:05 PM EDT - 1 year ago

Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Aug 28, 2024, 4:45 PM EDT - 2 years ago

Celularity Appoints Richard J. Berman to its Board of Directors

Aug 23, 2024, 5:00 PM EDT - 2 years ago

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Jul 31, 2024, 8:30 AM EDT - 2 years ago

Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023

Jul 30, 2024, 8:00 AM EDT - 2 years ago

Celularity Annual report: Q4 2023

Jun 3, 2024, 8:38 AM EDT - 2 years ago

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

May 21, 2024, 12:00 PM EDT - 2 years ago

Celularity Transcript: Analyst Research & Development Day 2024

May 21, 2024, 12:00 PM EDT - 2 years ago

Celularity Slides: FY 2024

May 14, 2024, 9:15 AM EDT - 2 years ago

Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy

Apr 22, 2024, 8:00 AM EDT - 2 years ago

Celularity Inc. to Host Investor and Analyst Research & Development Day

Apr 19, 2024, 5:30 PM EDT - 2 years ago

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Apr 18, 2024, 4:30 PM EDT - 2 years ago

Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products

Apr 8, 2024, 9:00 AM EDT - 2 years ago

Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells

Mar 26, 2024, 9:00 AM EDT - 2 years ago

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L

Mar 20, 2024, 9:15 AM EDT - 2 years ago

Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy

Mar 14, 2024, 9:15 AM EDT - 2 years ago

Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit

Mar 12, 2024, 9:20 AM EDT - 2 years ago

Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress

Mar 7, 2024, 9:35 AM EST - 2 years ago

Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells

Nosay Jul. 3 at 3:54 PM

2 · Reply

NuclearMan Jul. 2 at 11:09 AM

0 · Reply

1948Je Jun. 30 at 10:31 PM

$CELU Every stocks run a few hundred percent, Our time will be soon

0 · Reply

Nosay Jun. 30 at 8:23 PM

1 · Reply

focafoca99 Jun. 30 at 1:28 PM

$CELU took a $1 million loan from the Barach Family Trust, 4% interest, maturing 30 days after closing or receipt of financing.

0 · Reply

NuclearMan Jun. 30 at 12:54 PM

0 · Reply

NuclearMan Jun. 30 at 12:36 PM

0 · Reply

wolf_of_crypto_street Jun. 30 at 12:28 PM

$CELU this shit is headed to zero

0 · Reply

luckydog2 Jun. 30 at 4:41 AM

$CELU For anyone interested in learning about the many cell therapies offered at Fountain Life: https://www.reddit.com/r/CelularityNews/s/G52nijYh0c

0 · Reply

humorme Jun. 29 at 5:01 PM

1 · Reply

NuclearMan Jun. 26 at 3:32 PM

$CELU In the face of multiple delinquencies, the 8K on internal promotions is somewhat tone-deaf. The business is on the verge of closing Q2, and Q1 numbers are still AWOL. This is no way to run a company. Anyway SSR is active for the rest of today and Monday.

0 · Reply

focafoca99 Jun. 25 at 9:42 PM

$CELU makes Steven Gordon COO and board member, and K. Harold Fletcher chief legal and strategy officer.

0 · Reply

NuclearMan Jun. 25 at 1:38 PM

$CELU This is the problem. The Daily shows a descending wedge (usually bullish). The stock is SSR'd. It is 3 months since Q1 closed. CELU hired CFO Squad and have money. And despite all that handed on a gold plate, Hariri *still* cannot file a 10Q. So more drift and decline.

1 · Reply

NuclearMan Jun. 25 at 10:46 AM

$CELU I am not pumping this but will say that the last two day's high volume with low price volatility are the signs of short covering. My guess is they shorted from 4.00 to 70c and they will move on. At some point Hariri will get his act together and shorts won't want to be on the wrong side of the trade. Short Sale Restricted again today BTW.

2 · Reply

ToxicAvenger Jun. 24 at 9:28 PM

$CELU im still buying. Maybe im crazy but hey. The stuff works

2 · Reply

NuclearMan Jun. 24 at 7:57 PM

$CELU What gets me is Bob wrote a letter to shareholders while knowing he was nowhere near filing the 10Q. That was... bad.

0 · Reply

Nosay Jun. 24 at 2:57 PM

$CELU who’s the big fella with the great bid at .68. Love ya! 😘

1 · Reply

CharlieMungersghost Jun. 24 at 2:16 PM

$CELU where tf is bobby to. I cant imagine this stays public much longer.

0 · Reply

wolf_of_crypto_street Jun. 24 at 10:22 AM

$CELU what a piece of 💩

0 · Reply

topstockalerts Jun. 23 at 11:55 PM

After Hours Top Gainers PT2 $RCON $EPOW $SGLY $KWM $CELU

0 · Reply

SkywalkerAR Jun. 23 at 9:42 PM

$CELU https://www.lseg.com/content/dam/ftse-russell/en_us/documents/other/rmicro-deletions-20260612.pdf?hl=en-US

0 · Reply

NuclearMan Jun. 23 at 2:29 PM

$CELU The bear flag finally broke to the downside. The failure to file the 10Q means algos have nothing upon which to value the stock.

0 · Reply

Market Cap	17.94M
Revenue (ttm)	26.55M
Net Income (ttm)	-91.72M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-345.46%
Debt to Equity Ratio	-1.26

Volume	60,700
Avg Vol	163,822
Day's Range	N/A - N/A
Shares Out	28.95M
Stochastic %K	30%
Beta	0.54
Analysts	Sell
Price Target	$6.00